The Effect of Stellate Ganglion Block on Insomnia Patients

Zeng Changhao

Status: Enrolling

Conditions: Insomnia

Treatments: Procedure: Stellate Ganglion Block; Drug: Lidocaine Hydrochloride

Study type: Interventional

Funder types: Other

Identifiers

NCT06255730

SGB shimian old

Details and patient eligibility

About

A prospective study was conducted on Insomnia Patients. All the patients were provided with Stellate Ganglion Block. The quality of sleep was evaluated to see if Stellate Ganglion Block can improve Insomnia.

Full description

Insomnia is a sleep disorder characterized by difficulty falling asleep, staying asleep, or experiencing non-restorative sleep, despite having adequate opportunity for sleep. It is a common condition that can significantly impact an individual's quality of life and overall well-being.A prospective study was conducted on Insomnia Patients. All the patients were provided with Stellate Ganglion Block. The quality of sleep was evaluated to see if Stellate Ganglion Block can improve Insomnia.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Insomnia patients with the ages over 18.
• Meeting the diagnostic criteria for chronic insomnia as per the International Classification of Sleep Disorders (ICSD) or the Diagnostic and Statistical Manual of Mental Disorders (DSM).
• Experiencing insomnia symptoms persistently for at least three months.
• Not currently using or ceased using medication for insomnia for at least four weeks.
• Willing to undergo Stellate Ganglion Block treatment and participate in the study.

Exclusion criteria

• Patients with severe cardiovascular disease, pulmonary disease, or other serious physical health issues.
• Pregnant or lactating women.
• Patients with mental disorders (such as major depression, anxiety disorders, schizophrenia, etc.) or cognitive impairments.
• Patients with known allergies or contraindications to Stellate Ganglion Block treatment.
• Patients currently participating in other clinical trials or receiving experimental treatments.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Stellate Ganglion Block Group

Experimental group

Description:

Stellate Ganglion Block Group will be given Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day

Treatment:

Drug: Lidocaine Hydrochloride

Procedure: Stellate Ganglion Block